Literature DB >> 8776716

Interactions of excitatory amino acid antagonists with conventional antiepileptic drugs.

S J Czuczwar1, W A Turski, Z Kleinrok.   

Abstract

Excitatory amino acid antagonists possess anticonvulsant properties in many experimental models of epilepsy and were shown to potentiate the protective activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. Combined treatments of valproate with either D,L-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid or dizocilpine (NMDA antagonists), which provided a 50% protection against maximal electroshock, produced no side-effects, as measured in the chimney test (motor coordination) or passive avoidance task (long-term memory). Valproate alone at its ED50 against maximal electroshock, induced severe adverse effects. The NMDA antagonists, D-3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid, memantine, procyclidine, and trihexyphenidyl also potentiated the protective activity of conventional antiepileptics but these treatments were associated with considerable side-effects. The non-NMDA receptor antagonists, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline and 1-(amino-phenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine, also enhanced the anticonvulsive action of antiepileptic drugs against maximal electroshock, and these combinations generally resulted in no adverse effects. The potential clinical importance of some combinations of common antiepileptics with excitatory amino acid antagonists is postulated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8776716     DOI: 10.1007/bf02069501

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  51 in total

1.  Acidic amino acids with strong excitatory actions on mammalian neurones.

Authors:  D R CURTIS; J C WATKINS
Journal:  J Physiol       Date:  1963-04       Impact factor: 5.182

Review 2.  Excitatory amino acid receptors and synaptic plasticity.

Authors:  G L Collingridge; W Singer
Journal:  Trends Pharmacol Sci       Date:  1990-07       Impact factor: 14.819

Review 3.  Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity.

Authors:  S Nakanishi
Journal:  Neuron       Date:  1994-11       Impact factor: 17.173

4.  Differential effects of antiepileptic drugs and beta-carbolines on seizures induced by excitatory amino acids.

Authors:  L Turski; W Niemann; D N Stephens
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

5.  Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine.

Authors:  W Löscher; D Hönack
Journal:  J Pharmacol Exp Ther       Date:  1991-02       Impact factor: 4.030

6.  Effects of excitatory amino-acid antagonists on the anticonvulsant action of phenobarbital or diphenylhydantoin in mice.

Authors:  S J Czuczwar; L Turski; M Schwarz; W A Turski; Z Kleinrok
Journal:  Eur J Pharmacol       Date:  1984-05-04       Impact factor: 4.432

7.  Brain lesions in an infant rhesus monkey treated with monsodium glutamate.

Authors:  J W Olney; L G Sharpe
Journal:  Science       Date:  1969-10-17       Impact factor: 47.728

8.  Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline.

Authors:  L Turski; P Jacobsen; T Honoré; D N Stephens
Journal:  J Pharmacol Exp Ther       Date:  1992-02       Impact factor: 4.030

Review 9.  Properties of vertebrate glutamate receptors: calcium mobilization and desensitization.

Authors:  C F Zorumski; L L Thio
Journal:  Prog Neurobiol       Date:  1992-09       Impact factor: 11.685

10.  Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics.

Authors:  T Pietrasiewicz; G Czechowska; M Dziki; W A Turski; Z Kleinrok; S J Czuczwar
Journal:  Eur J Pharmacol       Date:  1993-11-30       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.